The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund focused on financing the development of drugs, vaccines, diagnostics, and other health interventions aimed at combating diseases that disproportionately affect low- and middle-income countries. GHIF targets late-stage innovations addressing public health challenges, including malaria, pre-eclampsia, cholera, HIV, and river blindness, while particularly emphasizing infectious diseases and maternal/infant health issues that contribute to significant morbidity and mortality in resource-limited settings. The fund also invests in initiatives to enhance access to existing products, such as pediatric formulations and improved vaccine stability. With a limited investment horizon, GHIF seeks opportunities with a high likelihood of successful commercialization within two to three years, prioritizing products that demonstrate dual market potential and high-volume, low-margin characteristics. The fund utilizes various investment structures, including mezzanine and convertible debt, preferred equity, and project financing, with an average investment target of around $10 million per project. Each initiative must align with GHIF's social impact goals while showing potential for commercial success.
Monod Bio is a life sciences company based in Seattle, Washington, focused on developing innovative biosensors for detecting proteins, toxins, antibodies, and other analytes. Founded in 2021, the company has created a biosensor platform that integrates binding, transduction, and amplification processes in a single step, allowing for the rapid and sensitive detection of a diverse array of target molecules. By leveraging recent advancements in computational protein engineering, Monod Bio has designed highly modular bio-sensing nanoswitches that facilitate cost-effective analytical assays. This technology aims to enhance the capabilities of the healthcare industry in biotechnology and medicine.
Endpoint Health
Series A in 2022
Endpoint Health, Inc. is a precision immunology company based in Palo Alto, California, with additional offices in Michigan and Illinois. Founded in 2018, the company focuses on researching and developing therapies that integrate therapeutics, companion diagnostics, and artificial intelligence. Its mission is to enhance patient outcomes, particularly for individuals suffering from critical illnesses such as sepsis, acute respiratory distress syndrome, and COVID-19. By utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health aims to identify and match effective therapies with patients who are most likely to benefit from them, moving beyond traditional one-size-fits-all approaches in drug development. Through this strategy, the company seeks to deliver personalized treatments that can significantly improve the health outcomes of patients with autoimmune and inflammatory conditions.
Eyenuk
Venture Round in 2020
Eyenuk, Inc. is a medtech company focused on developing artificial intelligence-based technology for retinal image analysis and disease detection. Founded in 2010 and based in Woodland Hills, California, Eyenuk's flagship product, the EyeArt AI Eye Screening System, is recognized for its extensive validation in the autonomous detection of diabetic retinopathy. The company also offers solutions such as EyeMark, which tracks retinopathy progression, and EyeApp, a mobile application that allows healthcare providers to conduct diabetic retinopathy screenings using smartphones. Additionally, Eyenuk provides EyeSeeAMD, a technology for identifying age-related macular degeneration. The company's mission is to screen every eye globally to ensure timely diagnosis of potentially life-threatening eye diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration, among others.
Alydia Health
Series C in 2020
Alydia Health, Inc. is a medical device company based in Menlo Park, California, focused on addressing postpartum hemorrhage (PPH), a leading cause of maternal mortality. The company designs and manufactures the Jada System, a device that effectively stops excessive bleeding by promoting natural uterine contractions after childbirth. This innovative solution utilizes a vacuum-induced tamponade effect, enabling the body to control postpartum hemorrhage without the need for pharmaceuticals or surgical interventions. Founded in 2010 and rebranded from InPress Technologies in 2018, Alydia Health aims to significantly enhance the treatment options for PPH, ultimately improving the health outcomes of women globally and reducing healthcare costs associated with maternal care.
Plethy
Seed Round in 2019
Plethy is an InsurTech and HealthTech company focused on enhancing patient outcomes and financial returns for self-insured enterprises, insurance carriers, and health systems. The company has developed a care management platform that helps patients manage their musculoskeletal care from the comfort of their homes or while on the go. This platform integrates a wearable sensor with a software application, allowing patients to adhere to their treatment plans effectively. By leveraging predictive analytics, Plethy provides valuable insights into patient recovery and claims closure, enabling healthcare providers to improve remote monitoring and achieve a balance between quality, access, and cost in patient care.
Themis Bioscience
Series D in 2019
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.
Alydia Health
Series B in 2018
Alydia Health, Inc. is a medical device company based in Menlo Park, California, focused on addressing postpartum hemorrhage (PPH), a leading cause of maternal mortality. The company designs and manufactures the Jada System, a device that effectively stops excessive bleeding by promoting natural uterine contractions after childbirth. This innovative solution utilizes a vacuum-induced tamponade effect, enabling the body to control postpartum hemorrhage without the need for pharmaceuticals or surgical interventions. Founded in 2010 and rebranded from InPress Technologies in 2018, Alydia Health aims to significantly enhance the treatment options for PPH, ultimately improving the health outcomes of women globally and reducing healthcare costs associated with maternal care.
Univercells
Series B in 2018
Univercells is a company specializing in high-density, low-cost biomanufacturing solutions aimed at enhancing the production of biologics, including antibodies, proteins, and vaccines. The company leverages innovative engineering and proprietary technologies, such as single-use systems and continuous process intensification, to significantly reduce capital investments by over 75% and the cost of goods by up to 90%. Univercells offers a range of services, including scale-X hydro, scale-X carbo, and NevoLine, which support both research and development and commercial-scale production of biologics. Additionally, the company provides integrated services like equipment confirmation, capacity and facility design, and bioprocess excellence, facilitating the scalability of cell and gene therapy manufacturers from clinical trials to commercial manufacturing. Through its commitment to making biologics more accessible and affordable, Univercells addresses critical global health challenges.
Themis Bioscience
Series C in 2018
Themis Bioscience N.V. is a clinical-stage biopharmaceutical company based in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead candidate, MV-CHIK, has successfully completed Phase II clinical trials for chikungunya treatment. Themis is also advancing vaccines targeting other infectious diseases, including Zika virus, Lassa fever, and MERS, along with developing therapeutics for cancer. Themis has established a research collaboration and exclusive licensing agreement with Merck & Co., enhancing its capabilities and market reach. The company is focused on progressing its innovative vaccine candidates through various clinical development phases while positioning itself as a valuable partner in the biotech and pharmaceutical sectors.
IanTech
Series C in 2017
IanTech, based in Reno, Nevada, specializes in the development of advanced micro-interventional technology for cataract surgery. The company has introduced a novel device that utilizes energy-free endocapsular lens fragmentation, allowing surgeons greater control and efficiency in performing cataract procedures. This pen-like device employs nitinol micro-filament technology to fragment the lens, facilitating its removal through a minimally invasive clear cornea incision. IanTech's innovative approach aims to enhance surgical outcomes and expand treatment options for a broader range of cataract cases. Additionally, the company is committed to addressing the global issue of cataract-related blindness, striving to reduce the impact of this condition through its cutting-edge surgical platform.
PATH
Venture Round in 2017
PATH is an international nonprofit organization that transforms global health through innovation. They take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential.
Atomo Diagnostics
Venture Round in 2016
Atomo Diagnostics is an Australian company that specializes in the research, design, development, and manufacturing of medical devices for blood-based rapid testing, applicable for both professional use and self-testing. Founded in 2010 and headquartered in Leichhardt, Australia, the company provides the AtomoRapid RDT platform, which supports various blood-based lateral flow test assays. These devices are utilized in screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics focuses on enhancing usability, safety, and accuracy in rapid diagnostic testing by integrating all test components into a streamlined solution, thereby reducing user error rates. The company operates internationally, with a presence in Europe, Asia, Africa, and Central and South America, and is led by a team experienced in commercializing innovative healthcare products. Its commitment to improving user experience distinguishes Atomo Diagnostics in the point-of-care testing market.
Access Bio
Post in 2016
Access Bio, Inc. is a biotechnology company based in Somerset, New Jersey, that specializes in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products. Founded in 2002, the company focuses on products aimed at the prevention and early diagnosis of infectious diseases. Its portfolio includes a range of rapid diagnostic tests such as CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM, as well as biosensors like the CareStart G6PD Biosensor. Additionally, Access Bio offers molecular diagnostic products, including CareStart HPV and CareStart CAH. The company's core technologies encompass immunochemical, biochemical, and molecular diagnostics.
Atomo Diagnostics
Debt Financing in 2016
Atomo Diagnostics is an Australian company that specializes in the research, design, development, and manufacturing of medical devices for blood-based rapid testing, applicable for both professional use and self-testing. Founded in 2010 and headquartered in Leichhardt, Australia, the company provides the AtomoRapid RDT platform, which supports various blood-based lateral flow test assays. These devices are utilized in screening for chronic conditions and detecting infectious diseases, including HIV. Atomo Diagnostics focuses on enhancing usability, safety, and accuracy in rapid diagnostic testing by integrating all test components into a streamlined solution, thereby reducing user error rates. The company operates internationally, with a presence in Europe, Asia, Africa, and Central and South America, and is led by a team experienced in commercializing innovative healthcare products. Its commitment to improving user experience distinguishes Atomo Diagnostics in the point-of-care testing market.
Becton, Dickinson and Company
Post in 2015
Becton, Dickinson and Company is a medical technology company focused on advancing health through improved medical discovery, diagnostics, and care delivery. The company manufactures a range of medical devices and instrument systems, including surgical and diagnostic systems, patient monitoring tools, and infusion products. BD is recognized for its commitment to enhancing patient and healthcare worker safety, as well as providing technologies that support medical research and clinical laboratories. Through its innovative products, BD aims to improve outcomes for both doctors and patients.
Genedrive
Post in 2014
genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade' business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.
EuBiologics
Series B in 2014
EuBiologics Co., Ltd. is a biopharmaceutical company based in Seoul, South Korea, focused on developing and supplying vaccines to address epidemics and antibiotic resistance. The company offers innovative products such as Euvchol, an oral cholera vaccine, and CRM197, a diphtheria toxin mutant vaccine. In addition to its vaccine development, EuBiologics provides customized services for the production of biopharmaceuticals derived from mammalian and microbial cells. These services encompass cell line development, GMP production, validation, and regulatory support. The company also specializes in the manufacture of recombinant biological products and antibody therapeutics. Furthermore, EuBiologics offers process development, formulation, analytical method development, and contract testing services, including lot release and stability testing. Founded in 2010, EuBiologics is dedicated to advancing healthcare solutions through its comprehensive biopharmaceutical capabilities.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.